Investigational drug · Phase 3
SAR445088
Also called: Riliprubart, BIVV020, Riliprubart Prefilled, PFP
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic, Transplant Rejection.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
4 still active
All registered trials
7
Any phase or sponsor naming "SAR445088"
First trial start
2021
Apr 28, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SAR445088", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Polyneuropathy, Inflammatory Demyelinating, Chronic
- Transplant Rejection
- Chronic Inflammatory Demyelinating Polyneuropathy
Approved drugs for the same conditions: Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "SAR445088" as an intervention, largest first.
- Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDPPivotal-lookingEnrolling by invitation
SanofiSanofi (SNY)
NCT06859099 · 300 participants (planned) · Start Apr 1, 2025 · Primary completion Oct 3, 2029
Drug: Riliprubart Prefilled Pen (PFP) · For: Polyneuropathy, Inflammatory Demyelinating, Chronic
Sites: Homewood, Alabama; Scottsdale, Arizona; Kansas City, Kansas · 63 sites in all
- A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Pivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT06290141 · 160 participants (planned) · Start Aug 21, 2024 · Primary completion Jul 9, 2027
Drug: riliprubart; Placebo and 4 more · For: Chronic Inflammatory Demyelinating Polyneuropathy
Sites: Homewood, Alabama; Scottsdale, Arizona; Los Angeles, California · 138 sites in all
- A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not WorkPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06290128 · 109 participants · Start Jul 12, 2024 · Primary completion Jun 10, 2026
Drug: Riliprubart; Placebo and 2 more · For: Chronic Inflammatory Demyelinating Polyradiculoneuropathy; Polyneuropathy, Inflammatory Demyelinating, Chronic
Sites: Homewood, Alabama; Los Angeles, California; Orange, California · 132 sites in all
- Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Completed
Bioverativ, a Sanofi companySanofi (SNY)
NCT04658472 · 98 participants · Start Apr 28, 2021 · Primary completion Oct 1, 2025
Drug: SAR445088 (IV); SAR445088 (SC) · For: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Sites: Los Angeles, California; Orange, California; Fairway, Kansas · 28 sites in all
- BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)Active, not recruiting
SanofiSanofi (SNY)
NCT05156710 · 48 participants · Start Jun 9, 2022 · Primary completion Oct 21, 2025
Drug: BIVV020 (SAR445088); Intravenous immunoglobulin (IVIg) and 5 more · For: Transplant Rejection
Sites: Los Angeles, California; San Francisco, California; Boston, Massachusetts · 27 sites in all
- A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)Completed
Bioverativ, a Sanofi companySanofi (SNY)
NCT04669600 · 12 participants · Start Feb 4, 2021 · Primary completion Feb 15, 2022
Drug: SAR445088 (BIVV020) · For: Immune Thrombocytopenia (ITP)
Sites: Washington D.C., District of Columbia; Tamarac, Florida; Ostrava - Poruba, Czechia · 9 sites in all
Bioverativ, a Sanofi companySanofi (SNY)
NCT04802057 · 9 participants · Start Mar 22, 2021 · Primary completion Mar 4, 2025
Drug: SAR445088 · For: Autoimmune Haemolytic Anaemia
Sites: Essen, Germany; Milan, Italy; Amsterdam, Netherlands · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Ultrasound-responsive nanotherapy promotes axonal regeneration after SCI via reactivating CREB/miR-129-5p signaling.
Gu G, Zhu H, Li S, et al. · Bioact Mater 2027
- Ultrasound-responsive and size-transformable self-carrier nanodroplets for augmented deep vein thrombosis therapy.
Lin Y, Zheng J, Huang Z, et al. · Biomaterials 2027
- Development and Validation of a Stability-Indicating HPLC Method for Degarelix and Characterization of Its Degradation Impurities Using LC-MS, 1H NMR, and FTIR Techniques.
Simhachalam P, Sabithakala T · Biomed Chromatogr 2027
- Using the Function Prediction Server and Queryome for Functional Protein Design.
Punuru P, Giri S, Kihara D · Methods Mol Biol 2027
- Passion fruit pectins differentially modulate toll-like receptors, macrophages, and epithelial wound healing according to molecular size.
Pedrosa LF, Galvez-Jiron F, Gasaly N, et al. · Carbohydr Polym 2026
- Chairside frailty screening in hemodialysis patients: diagnostic accuracy of the Kihon Checklist combined with calf circumference.
Wu CF, Kuo HL, Wu CJ, et al. · Ren Fail 2026
Also in development for Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- EmpasiprubartARGX-117Phase 39 trials
argenx · Multifocal Motor Neuropathy (MMN), Chronic Inflammatory Demyelinating Polyneuropathy, CIDP
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.